Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin–vinorelbine with a cisplatin–vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study
Maurice Pérol, H. Léna, P. A. Thomas et al. · Annals of Oncology · 2002
Cited by 17 works. doi:10.1093/annonc/mdf128
Authors
- Maurice Pérol
- H. Léna
- P. A. Thomas
- G. Robinet
- P. Fournel
- C. Belleguic
- H. Le Caer
- François Blanchon
- Alain Vergnenégre
- J.‐M. Vernejoux
- M.P Schuller-Lebeau
- Erica Pham
References
- Reporting results of cancer treatment
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
- One-Sample Multiple Testing Procedure for Phase II Clinical Trials
- Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and-resistant human ovarian carcinoma cell lines
- A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)
- Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trial
- A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC)
- Pathologic stage IIIb non-small cell lung cancer (NSCLC): Prolonged survival with consoloidation Docetaxel following concurrent chemoradiotherapy (SWOG 9504)
- Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer.